---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-074330"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:35:23.466134+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# CEO presents Pearsanta IPO plans; commercialization target Q1 2026

## Summary
- CEO Amro Albanna presented at Wall Street Reporter livestream; discussed Pearsanta IPO plans.
- Pearsanta's cancer diagnostics platform uses mitochondrial DNA blood tests; initial targets prostate cancer and endometriosis.
- Commercial launch of first tests targeted for end of 2025 / Q1 2026 after validation studies.
- Pearsanta IPO planned for early first half 2026 with Spartan Capital as underwriter.
- Aditxt strategy: acquire health innovations, build in-house, monetize via events like Pearsanta IPO.

## SEC filing metadata
- accession: 0001213900-25-074330
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025074330/0001213900-25-074330-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025074330/ea0252550-8k_aditxt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-074330
- JSON: https://secwatch.observer/filing/0001213900-25-074330.json
- Plain text: https://secwatch.observer/filing/0001213900-25-074330.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.